Anti-NMDA receptor encephalitis
MONDO:0021081An autoimmune acute encephalitis caused by antibodies against the glutamate NMDA receptor. It usually affects females and in the majority of cases it is associated with the presence of a tumor, most commonly an ovarian teratoma. The presence of a tumor in patients with this form of encephalitis implies that the latter is a paraneoplastic syndrome. It is manifested with psychiatric symptoms and epileptic seizures. It is a potentially lethal disorder; however, it is usually reversible with the prompt removal of the tumor.
Also known as: anti-NMDA receptor encephalitis, limbic encephalitis with N-methyl-D-aspartate receptor antibodies, limbic encephalitis with NMDA receptor antibodies
11 clinical trials for this condition and its sub-types, 9 tagged with Anti-NMDA receptor encephalitis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
Can an antibody-clearing drug blunt a brain-attacking immune attack?
Disease control Recruiting nowResearchers are testing efgartigimod, an intravenous drug that reduces certain antibodies, in adults with anti-NMDAR encephalitis, a rare autoimmune condition that causes psychiatric symptoms, seizures, and movement problems. The trial enrolls 20 participants who receive four wee…
Phase 2 • Sponsor: Beijing Tongren Hospital • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New combo therapy targets Brain-Attacking antibodies in severe encephalitis
Disease control Recruiting nowThis study tests whether combining two drugs—ofatumumab and daratumumab—can safely and effectively treat people with severe anti-NMDAR autoimmune encephalitis, a condition where the immune system attacks the brain. The drugs aim to eliminate the harmful immune cells producing the…
Phase 3 • Sponsor: The First People's Hospital of Changzhou • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New antibody drug aims to block Brain-Attacking autoantibodies
Disease control Recruiting nowThis Phase 2a trial tests a drug called ART5803 in 30 adults with anti-NMDAR encephalitis or related psychiatric disease. The drug is a lab-made antibody designed to block harmful autoantibodies from attacking brain receptors. The study focuses on safety and tolerability, with ea…
Phase 2 • Sponsor: Arialys Australia Pty Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Rapid brain infection test could slash unnecessary antibiotic use
Diagnosis Recruiting nowThis study looks at whether a quick diagnostic test (BioFire FilmArray) can accurately predict the cause of meningitis or encephalitis in 182 adults. Participants with symptoms like fever, headache, or confusion will have their spinal fluid tested. The goal is to see if the test …
Sponsor: Federal University of Health Science of Porto Alegre • Aim: Diagnosis
Last updated Aug 23, 2026 00:00 UTC
-
Hunting for hidden antibodies in brain inflammation
Knowledge-focused Recruiting nowThis study aims to better understand autoimmune encephalitis, a condition where the immune system attacks the brain. Researchers will analyze blood and spinal fluid from 20 patients to find new antibodies that may explain the disease in people who currently test negative. The goa…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Life after brain inflammation: new study probes hidden scars of rare disease
Knowledge-focused Recruiting nowThis study looks at the long-term social and emotional challenges faced by people who have had NMDA receptor encephalitis, a rare brain inflammation. Researchers will ask 30 adults to complete questionnaires about fatigue, anxiety, depression, sleep, and quality of life. The goal…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC